Semaglutide · source year
3 selected, source-linked Semaglutide records carrying a 2019 source date. This is a navigational view of PeptideScanner’s selected coverage—not a complete research timeline or a statement about safety or effectiveness.
3 selected records.
2 represented types.
3 distinct public records.
Cited chronology
Regulatory
The Federal Register published notice 2019-25850, attributed to FDA and its parent HHS department, on 2019-11-29. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; OZEMPIC,” and PeptideScanner's exact reviewed identity mapping connects the document to Semaglutide.
Source: Federal Register via GovInfo ↗
Regulatory
The official Drugs@FDA dataset lists original submission 1 for NDA 213051 with status AP dated 2019-09-20, and names semaglutide among the application record's active ingredients.
Source: Drugs@FDA via openFDA ↗
Clinical trials
PeptideScanner retained ClinicalTrials.gov record NCT03466567 at 2026-07-30T20:50:35.918Z. Its registry update date was 2019-06-19, and PeptideScanner's reviewed identity mapping was semaglutide.
Source: ClinicalTrials.gov ↗